UK markets close in 52 minutes

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
85.80-0.14 (-0.16%)
As of 04:23PM CET. Market open.
Full screen
Previous close85.94
Bid0.00 x 0
Ask0.00 x 0
Day's range85.74 - 86.54
52-week range76.45 - 106.66
Avg. volume1,875,817
Market cap110.881B
Beta (5Y monthly)0.42
PE ratio (TTM)16.82
Earnings dateN/A
Forward dividend & yield3.33 (3.88%)
Ex-dividend date06 May 2022
1y target estN/A
  • Motley Fool

    Why Shares of Provention Bio Went Up 30.3% in November

    Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.

  • Reuters

    Sanofi says any offer for Horizon Therapeutics, if made, will be in cash

    PARIS (Reuters) -French drugmaker Sanofi said on Friday that if it decides to bid for biotech company Horizon Therapeutics Plc, it would do so in cash. Horizon Therapeutics Plc, which has a market capitalization of about $18 billion, is in talks with Amgen Inc, Sanofi and Johnson & Johnson unit Janssen Global Services over potential takeover offers.

  • Bloomberg

    Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J

    (Bloomberg) -- Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatStock Traders Cheer Powell’s Risk-Friendly Shift: Markets WrapNYC Becomes One Billionaire Family’s Haven From China Property Crash